Aspen has reported an annual revenue increase of 9 per cent to R38.6 billion boosted by growth from Commercial Pharmaceuticals and 22 per cent increase from its Manufacturing sector. The group has not declared an annual dividend amid the volatile market conditions, but it continues to ramp up production of its COVID-19 treatment drug dexamethasone. Aspen CEO, Stephen Saad joins CNBC Africa for more.
JOHANNESBURG (Reuters) - South Africa’s Aspen Pharmacare Holdings Ltd expects growth in its headline earnings per share (HEPS) from continuing operations of between 7-11% for the full year that ended...
BRUSSELS (Reuters) - Aspen (APNJ.J) has offered to cut prices by an average of 73% for six off-patent cancer drugs, EU antitrust regulators said on Tuesday, a move that could...
A long standing drug called Dexamthasone - a cheap anti -inflammatory steroid - can save lives. Oxford University researchers say the drug could have saved 5,000 lives in Britain alone. It turns out that South Africa has had the drug all along. A version of it called Decasone is made by Aspen. It is a schedule four prescription drug that is injected to ease inflammation for ailments like arthritis. Aspen CEO, Stephen Saad spoke to CNBC Africa for more.
What do Omnia, Aspen and Nampak all have in common? They are the increasing number of JSE-listed companies that have analysts and shareholders concerned about their debt. CNBC Africa’s Kopano Gumbi spoke to packaging company Nampak’s CEO André de Ruyter about its debt and why he is really concerned about South Africa.
Metal can manufacturer Nampak has been struggling to find its footing in the declining economy and some investments, but a green shoot is sprouting in Nigeria and the CEO Andre de Ruyter remains optimistic that it can turn the business around. He sat down with CNBC Africa reporter Kopano Gumbi.